23 May 2013
Keywords: QrXPharma, MoxDuo IR, Pain, Actavis, US opioid market
Article | 29 March 2012
Australian company QRxPharma (ASX: QRX) is moving rapidly towards the commercial phase for its lead product, MoxDuo IR, an immediate ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
29 March 2012
© 2013 thepharmaletter.com